by The global antiemetics drugs market was surpassed at USD 7.52 billion in 2022 and is expected to hit around USD 13.45 billion by 2032, growing at a CAGR of 5.99% from 2023 to 2032.
Key Pointers
- North America dominated the market with the largest market share of 37% in 2022.
- The Asia Pacific market is poised for significant growth, projected to achieve a noteworthy CAGR from 2023 to 2032
- By Drug Type, the serotonin-receptor antagonists segment secured the largest market share at 30% in 2022.
- By Application, the chemotherapy segment contributed the largest market share of 46% in 2022.
- By Application, the postoperative surgery segment is forecasted to exhibit the fastest CAGR from 2023 to 2032.
- By End-use, the retail pharmacies segment asserted its dominance in the market, securing a substantial revenue share of 48% in 2022.
The antiemetics drugs market is a critical segment within the pharmaceutical industry, dedicated to addressing the challenges of nausea and vomiting, prevalent symptoms associated with various medical conditions and treatments. This overview aims to provide a comprehensive understanding of the antiemetics drugs market, covering key aspects such as market definition, current landscape, and future prospects.
Get a Sample: https://www.visionresearchreports.com/report/sample/41038
Report Scope of the Antiemetics Drugs Market
| Report Coverage | Details |
| Market Revenue by 2032 | USD 13.45 billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.99% |
| Revenue Share of North America in 2022 | 37% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Anti-nausea and vomiting medications are employed to manage and prevent conditions like gastroenteritis and cancer. The expansion of the market can be attributed to the increasing occurrences of these ailments and the ongoing growth in research and development activities. Additionally, the rise in the introduction of generic alternatives is another factor shaping the demand in the market.
The increasing occurrences of diseases like gastroenteritis and cancer, which can lead to nausea and vomiting, are expected to drive up demand. Therapies such as chemotherapy for cancer and treatments for gastroenteritis often result in adverse effects, including nausea and vomiting. Antiemetic drugs play a crucial role in managing these side effects during treatments, leading to an anticipated increase in demand due to the growing prevalence of cancer and gastroenteritis.
According to the American Cancer Society, it is estimated that around 609,820 cancer deaths and 1,958,310 new cancer cases will occur in the U.S. in 2023. Additionally, a study published by NCBI in January 2019 highlighted the high prevalence of rotavirus gastroenteritis in India. Consequently, the rising incidence of diseases causing vomiting and nausea is expected to fuel market growth throughout the forecast period.
Moreover, the market is likely to expand further with the increasing number of drug approvals and ongoing research activities. Numerous industry participants are actively engaged in the research, development, and approval processes for antiemetic drugs. For example, in March 2022, Taiho Pharmaceutical Co., Ltd. received authorization to market and manufacture Arokaris, a selective NK1 receptor antagonist antiemetic drug designed for gastrointestinal symptoms associated with cancer chemotherapy. The introduction and approval of such products are poised to be significant drivers of market growth in the forecast period.
Drug Type Insights
In 2022, the serotonin-receptor antagonists segment secured the largest market share at 30% and it is poised to experience the swiftest growth throughout the forecast period. This segment encompasses drugs such as Ondansetron (Zofran), Dolasetron (Anzemet), and Granisetron (Kytril), available in both injection and oral pill formulations. The notable market share and anticipated growth of this segment can be attributed to the increasing utilization of serotonin-receptor antagonist drugs to mitigate nausea and vomiting associated with chemotherapy, radiation therapy, and anesthesia. This trend is further accentuated by the escalating global incidence of cancer.
The dopamine receptor antagonist drugs segment held the second-largest market share, featuring drugs like Barhemsys, Inapsine, Haldol, Reglan, Gimoti, and Thorazine. The growth in this segment is attributed to the mounting approvals received by these drugs from regulatory authorities. For instance, in February 2020, BARHEMSYS, an antiemetic drug, obtained FDA approval for the prevention or treatment of postoperative nausea and vomiting.
Application Insights
In 2022, the chemotherapy segment contributed the largest market share of 46%. The heightened revenue share of this segment can be attributed to the increasing utilization of antiemetic drugs for managing nausea and vomiting associated with chemotherapy, coupled with a surge in product launches within this domain. Notably, in May 2018, in Brazil, Helsinn, a Swiss pharmaceutical company, in collaboration with Mundipharma, introduced the oral hard capsule AKYNZEO, designed to address nausea and vomiting induced by both acute and delayed phases of chemotherapy.
The postoperative surgery segment is forecasted to exhibit the fastest CAGR from 2023 to 2032. The anticipated growth in this segment is fueled by the growing adoption of antiemetic drugs to mitigate postoperative vomiting and nausea. Additionally, the prevalence of adverse effects, such as nausea and vomiting due to anesthesia, is expected to contribute to segmental growth throughout the forecast period. As highlighted in a November 2020 article by the Association of Anesthetists, approximately 30% of the general surgical population and about 80% of high-risk patients experience postoperative vomiting and nausea.
End-use Insights
In 2022, the retail pharmacies segment asserted its dominance in the market, securing a substantial revenue share of 48%. The growth of this segment is fueled by the convenience and product availability offered by retail pharmacies. Additionally, the widespread presence of major retail pharmacy chains such as CVS Pharmacy, Walgreens Boots Alliance, and Rite Aid on a global scale is expected to drive the demand for these medications throughout the forecast period.
Conversely, the other segment, encompassing the procurement of drugs through online platforms or e-commerce, is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period. The expansion of this segment can be attributed to the increasing penetration of smartphones and the internet worldwide, a growing awareness of online pharmacies, and the industry’s increasing emphasis on fortifying their online distribution networks. According to a study published in Frontiers in December 2022, approximately 92.8% of respondents were aware that they could purchase medicines online.
Regional Insights
In 2022, North America dominated the market with the largest market share of 37%. The region’s leadership is bolstered by the presence of key players such as Pfizer and GSK plc, contributing to a higher revenue share. Additionally, the ongoing approvals for antiemetic drugs in North America are expected to fuel further regional expansion. Notably, a May 2022 article from the Canadian Institutes of Health Research highlighted the approval of Ondansetron, a 5-HT3 antagonist, in Canada for use as an antiemetic in managing nausea and vomiting associated with chemotherapy and post-operation scenarios.
The Asia Pacific market is poised for significant growth, projected to achieve a noteworthy CAGR from 2023 to 2032. This trajectory is supported by the increasing incidences of cancer and gastroenteritis across the region, coupled with the expanding availability of various antiemetic medications. A November 2022 study published by the National Library of Medicine revealed a projected 12.8% increase in cancer cases in India within the five-year period from 2020 to 2025. Consequently, the escalating incidences of cancer, coupled with the growing prevalence of chemotherapy, are anticipated to be key drivers of regional growth throughout the forecast period.
Key Companies
- Pfizer Inc.
- Cipla Inc.
- Merck KGaA
- Eagle Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- GSK plc.
- Astellas Pharma Inc.
- GLENMARK PHARMACEUTICALS LTD.
- Viatris Inc.
- Baxter
Antiemetics Drugs Market Report Segmentations:
By Drug Type
- Serotonin-receptor Antagonists
- Anticholinergics
- Dopamine Receptor Antagonists
- Neurokinin Receptor Antagonists
- Others (Antihistamines, Cannabinoids)
By Application
- Chemotherapy
- Gastroenteritis
- Post Operative Surgery
- Others
By End-use
- Hospital & Clinics
- Retail Pharmacy
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41038
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
